By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synthetic Biologics, Inc. 

3930 Varsity Drive

Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-7800 Fax: 734-332-7878


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Synthetic Biologics (SYN) Release: SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation From FDA For Prevention Of Clostridium Difficile Infection 5/11/2017 6:47:54 AM
Synthetic Biologics (SYN) Reports First Quarter 2017 Operational Highlights And Financial Results 5/5/2017 8:43:19 AM
Synthetic Biologics (SYN) To Report First Quarter 2017 Operational Highlights And Financial Results On May 4, 2017 4/27/2017 10:03:19 AM
Synthetic Biologics (SYN) Reports Preclinical Data Demonstrating SYN-005 Provides Protection From Pertussis In Neonatal Animal Study 4/19/2017 6:34:42 AM
Synthetic Biologics (SYN) Reports 2016 Year End Operational Highlights And Financial Results 3/3/2017 9:45:48 AM
Synthetic Biologics (SYN) To Report 2016 Year End Operational Highlights And Financial Results On March 2, 2017 2/22/2017 9:05:09 AM
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA 1/19/2017 7:26:16 AM
Synthetic Biologics (SYN)' SYN-004 (Ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI) 1/5/2017 6:23:14 AM
Synthetic Biologics (SYN) Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough) 12/13/2016 6:15:04 AM
Synthetic Biologics (SYN) Announces Closing Of Public Offering Of Common Stock And Warrants 11/21/2016 7:21:34 AM
12345678910...
//-->